Overview of high-risk Food and Drug Administration recalls for cosmetics and personal care products from 2002 to 2016

被引:7
|
作者
Janetos, Timothy M. [1 ]
Akintilo, Lisa [2 ]
Xu, Shuai [2 ]
机构
[1] Northwestern Univ, Dept Ophthalmol, McGaw Med Ctr, Chicago, IL 60611 USA
[2] Northwestern Univ, McGaw Med Ctr, Dept Dermatol, Chicago, IL 60611 USA
关键词
cosmetic recalls; cosmetic safety; Food and Drug Administration; moisturizers; personal care products; sunscreens; UNIT;
D O I
10.1111/jocd.12824
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: There have been several recent controversies surrounding cosmetic products that have impacted health. Dermatologists are often the first to encounter these issues, and recalls are one metric of a safety profile of cosmetics and their impact on health. Objective: To analyze all recalls of cosmetic and personal care products from 2002 to 2016. Methods: This observational study describes all FDA cosmetic and personal care product recalls, acquired via a Freedom of Information Act request, from 2002 to 2016. The total number of Class I, Class II, and Class III recalls, number and origin of manufacturers, number of products affected, and main reason for recall were collected. Results: A total of 14 Class I, 266 Class II, and 33 Class III recalls were recorded. Baby products comprised the largest product category accounting for 24% of all recalls (76/313). 76% of recalls were due to bacterial contamination (237/313), followed by unapproved components, labeling issues, and skin irritation. The 14 Class I recalls accounted for 1.9 million products in distribution. Conclusions: Cosmetic recalls impacted millions of products and had the potential to cause serious harm. Dermatologists have the ability to strengthen public safety by reporting adverse events, encouraging recalls of harmful products, and lobbying through dermatology organizations for meaningful change to current cosmetic regulation.
引用
收藏
页码:1361 / 1365
页数:5
相关论文
共 35 条
  • [31] The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial
    Bakker, Tinka
    Klopotowska, Joanna E.
    Dongelmans, Dave A.
    Eslami, Saeid
    Vermeijden, Wytze J.
    Hendriks, Stefaan
    ten Cate, Julia
    Karakus, Attila
    Purmer, Ilse M.
    van Bree, Sjoerd H. W.
    Spronk, Peter E.
    Hoeksema, Martijn
    de Jonge, Evert
    de Keizer, Nicolette F.
    Abu-Hanna, Ameen
    LANCET, 2024, 403 (10425): : 439 - 449
  • [32] Inclusion of demographic-specific information in studies supporting US Food & Drug Administration approval of high-risk medical devices (vol 177, pg 1390, 2017)
    Dhruva, S. S.
    Mazure, C. M.
    Ross, J. S.
    Redberg, R. F.
    JAMA INTERNAL MEDICINE, 2017, 177 (09) : 1400 - 1400
  • [33] Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    Busetto, Gian Maria
    Finati, Marco
    Chirico, Marco
    Cinelli, Francesco
    D'Altilia, Nicola
    Falagario, Ugo G.
    Sanguedolce, Francesca
    Del Giudice, Francesco
    De Berardinis, Ettore
    Ferro, Matteo
    Crocetto, Felice
    Porreca, Angelo
    Di Gianfrancesco, Luca
    Calo, Beppe
    Mancini, Vito
    Bettocchi, Carlo
    Carrieri, Giuseppe
    Cormio, Luigi
    WORLD JOURNAL OF UROLOGY, 2023, 41 (05) : 1329 - 1335
  • [34] Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    Gian Maria Busetto
    Marco Finati
    Marco Chirico
    Francesco Cinelli
    Nicola D’Altilia
    Ugo G. Falagario
    Francesca Sanguedolce
    Francesco Del Giudice
    Ettore De Berardinis
    Matteo Ferro
    Felice Crocetto
    Angelo Porreca
    Luca Di Gianfrancesco
    Beppe Calo’
    Vito Mancini
    Carlo Bettocchi
    Giuseppe Carrieri
    Luigi Cormio
    World Journal of Urology, 2023, 41 : 1329 - 1335
  • [35] Genomic Insights into Vietnamese Extended-Spectrum β-Lactamase-9-Producing Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Belonging to the High-Risk Clone ST357 Obtained from Bulgarian Intensive Care Unit Patients
    Strateva, Tanya
    Stratev, Alexander
    Peykov, Slavil
    PATHOGENS, 2024, 13 (09):